The Filing Desk

Ovid Therapeutics vs Xenon Pharmaceuticals

Ovid Therapeutics OVID · Xenon Pharmaceuticals XENE · Pharmaceuticals

Xenon Pharmaceuticals reported revenue of $8 million in fiscal 2025, about the same as Ovid Therapeutics' $7 million in fiscal 2025. Ovid Therapeutics had an operating margin of -585.2%, against -4974.3% at Xenon Pharmaceuticals. Free cash flow was −$38 million at Ovid Therapeutics and −$280 million at Xenon Pharmaceuticals.

Side by side

Ovid TherapeuticsXenon Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$7M$8M
Revenue growth1,181.3%—
Revenue growth a year, last 5 years−10.3%−25.3%
Gross margin——
Operating margin−585.2%−4,974.3%
Net margin−240.1%−4,612.1%
Free cash flow−$38M−$280M
Free cash flow margin−528.6%−3,732.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count—1.7%
Last close$2.54$40.48
P/E at the last close——
Insider trades, last 12 months—sold $22.0 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Ovid TherapeuticsXenon Pharmaceuticals
Operating margin
Percent of revenue
Ovid TherapeuticsXenon Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ovid TherapeuticsXenon Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ovid Therapeutics and Xenon Pharmaceuticals pages.